Clinical trial
A Prospective, Double Blind, Randomized, Placebo-Controlled Phase III Trial of Imatinib Re-Challenge in Patients With Gastrointestinal Stromal Tumor Who Had Benefit From Prior Imatinib But Progression From Both Imatinib and Sunitinib
NCT01151852 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Double Blind, Randomized, Placebo-Controlled Phase III Trial of Imatinib Re-Challenge in Patients With Gastrointestinal Stromal Tumor Who Had Benefit From Prior Imatinib But Progression From Both Imatinib and Sunitinib
- Lead sponsor
- Asan Medical Center
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2010
- Completion date
- March 31, 2013
- Enrollment
- 81 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.